Nuveen Fund Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Nuveen Fund Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-942	Closed	-$381K	–	98
2018 Q3	$381K	Sell	942 -851	-47%	-$324K	0.85%	42
2018 Q2	$619K	Sell	1,793 -845	-32%	-$264K	0.76%	40
2018 Q1	$908K	Sell	2,638 -168	-6%	-$58.4K	0.42%	66
2017 Q4	$1.05M	Sell	2,806 -1,276	-31%	-$517K	0.31%	85
2017 Q3	$1.82M	Sell	4,082 -566	-12%	-$269K	0.37%	77
2017 Q2	$2.28M	Sell	4,648 -2,242	-33%	-$981K	0.36%	82
2017 Q1	$2.67M	Sell	6,890 -469	-6%	-$174K	0.35%	100
2016 Q4	$2.7M	Sell	7,359 -473	-6%	-$180K	0.39%	88
2016 Q3	$3.15M	Buy	7,832 +251	+3%	+$101K	0.44%	67
2016 Q2	$2.65M	Buy	+7,581	New	+$2.92M	0.41%	78

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Fund Advisors's REGN Position: Q4 2018 in Review

Nuveen Fund Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 942 shares — an estimated $381K sold.

Nuveen Fund Advisors first reported a position in REGN in Q2 2016 and held it in 10 quarters. The position peaked at $3.15M in Q3 2016. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Nuveen Fund Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Nuveen Fund Advisors sold 942 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $381K.
Nuveen Fund Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 10 quarters.
Nuveen Fund Advisors's Regeneron Pharmaceuticals position peaked at $3.15M in Q3 2016.
670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Nuveen Fund Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.